A quiet revolution in care is helping patients with cardiac amyloidosis, a form of heart failure that long stumped doctors.

Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...

Amyloidosis is classified into three main forms depending on the cause of the condition. The condition is also referred to as either localized when only one site of the body is affected, or ...

Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials.

In fact in Primary Amyloidosis (most common type of amyloidosis) the abnormal protein produced is called the ‘amyloid light chains’ and this gets accumulated in organs such as the heart, lungs ...

So, for AL amyloidosis, we can offer chemo therapy and even a bone marrow transplantation with very good outcomes with several years of survival. I have a patient with a diagnosis of AL amyloidosis ...

Cardiac amyloidosis is not nearly as rare as one might think, and with effective treatments finally emerging in recent years, there’s a need to increase awareness of the condition to allow for earlier ...

PITTSBURGH (KDKA) -- Amyloidosis is a rare condition that used to almost always be fatal, but doctors are finally making progress in treating it. "I had so many symptoms, and I really didn't think ...

Cardiac amyloidosis in Danish population The median age at initial cardiac amyloidosis diagnosis increased from 67.4 years in 1998-2002 to 72.3 years in 2013-2017.

The RNAi therapeutic patisiran improves functional capacity and quality of life in ATTR amyloidosis with cardiomyopathy, topline results of APOLLO-B show. The company will seek an FDA supplemental ...

The US Food and Drug Administration (FDA) has approved vutrisiran (Amvuttra, Alnylam Pharmaceuticals) for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis ...